YD Bio Ltd (YDES)
YDESNASDAQ-GMMedical Specialities
$4.73
+0.2630 (+5.89%) today
Closed, Nov 17, 4:00 PM ET
- Market cap
- $342.12m
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- –
- 52-week range
- $1.70 to $15.72
- Average volume
- –
- Previous close
- $4.47
Financials
No quarterly figures from the source.
News
7 latest- YD Bio Expects FDA Feedback On Dry Eye Candidate By January 4, 2027 RTTNews · 5 days ago
- After-Hours Gainers: PFSA Executes Another Reverse Split, IVF Jumps On Q2 Results, AMLX Faces D-Day RTTNews · Aug 17, 2026
- Top Biotech Gainers: LUCY Shines, SEER Gets Takeover Offer, OFIX, ENOV Rally On CMS Update RTTNews · Jul 6, 2026
- YD Bio Shares Becomes Oversold (YDES)BNK Invest · Apr 16, 2026
- Weekly Buzz: Intellia Gets FDA Nod For ATTRv-PN Trial; Aprea's APR-1051 Paces; CALC Halts KOURAGE RTTNews · Jan 30, 2026
- YD Bio Signs LOI To Acquire Safe Save Medical, Expanding Immunocell Therapy Leadership RTTNews · Jan 29, 2026
- YD Bio Outlines An Ambitious 2026 Roadmap Following A Transformative 2025 RTTNews · Jan 6, 2026
The company
YD Bio is a U.S.-anchored public biotechnology company building an integrated healthcare platform spanning regulated molecular diagnostics, clinical services, precision medicine, and life science commercialization. The Company operates DNA methylation-based oncology testing programs in the United States under a laboratory-developed test strategy and supports pharmaceutical and biotechnology partners through compliant life science distribution and clinical trial supply chain services. In addition, the Company maintains regulated ocular health commercialization operations and a consumer health distribution platform in Asia. For more information, visit ir.ydesgroup.com and follow the Company on Facebook, X, Threads, Instagram and LinkedIn.
- Sector
- Health Care
- Industry
- Medical Specialities
- Exchange
- NASDAQ-GM
- Region
- North America
- Website
- ydesgroup.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.